Welcome to our dedicated page for Akebia Therapeut news (Ticker: AKBA), a resource for investors and traders seeking the latest updates and insights on Akebia Therapeut stock.
Akebia Therapeutics, Inc. develops and commercializes therapeutics for people impacted by kidney disease. Company news commonly covers Vafseo® (vadadustat), an oral HIF-PH inhibitor indicated for anemia due to chronic kidney disease in adults receiving dialysis, and Auryxia® (ferric citrate), a U.S.-marketed therapy for chronic kidney disease-related conditions.
Recurring updates also address product revenue, dialysis-market access, clinical data publications, and kidney disease pipeline programs, including praliciguat in focal segmental glomerulosclerosis, AKB-097 in rare kidney diseases, and AKB-9090 for cardiac surgery-associated acute kidney injury. Akebia also reports Nasdaq inducement grants, board changes, investor presentations, and quarterly financial results.
Akebia Therapeutics (Nasdaq: AKBA) reported Q2 2026 total revenues of $49.1 million, down from $62.5 million a year earlier, as Auryxia revenues fell to $25.5 million amid generic competition. Vafseo net product revenues grew to $21.3 million, up 34% sequentially and from $13.3 million in Q2 2025.
More than 10,500 patients were on Vafseo in Q2, a 41% increase from Q1, with prescribers rising to about 1,200. Akebia reported a net loss of $8.9 million versus net income of $0.2 million a year ago, and held $155.5 million in cash and equivalents at June 30, 2026, which it believes funds operations for at least two years. The company advanced its rare kidney disease pipeline with a Phase 2 basket trial of ebribafusp and continued a Phase 2 trial of praliciguat. An interim analysis of the VOICE trial showed statistically significant improved safety outcomes for Vafseo versus an ESA on a composite of all-cause mortality and hospitalization, and Akebia strengthened Vafseo intellectual property with additional Orange Book–listed patents extending coverage out to 2036.
Akebia Therapeutics (Nasdaq: AKBA) granted stock options to two newly hired employees on July 31, 2026, covering an aggregate 61,000 shares of common stock as inducement awards under Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $1.32 per share, equal to the closing price on the grant date.
The options vest over four years, with 25% vesting on the first anniversary and the remaining 75% vesting quarterly thereafter, subject to continued service. Each option has a 10-year term and is granted under Akebia’s inducement award program and a related stock option agreement.
Akebia Therapeutics (Nasdaq: AKBA) has initiated an open-label Phase 2 basket trial of ebribafusp, a next-generation complement inhibitor, in rare complement-mediated kidney diseases: IgA nephropathy (IgAN), lupus nephritis (LN), and C3 glomerulopathy (C3G). The study will evaluate safety, efficacy, and pharmacokinetics of once-weekly subcutaneous dosing over 26 weeks in up to 30 patients, followed by a long-term extension for responders.
The trial’s primary endpoint is incidence of adverse events, with secondary endpoints including changes in proteinuria (UPCR), kidney function (eGFR), and pharmacokinetics, plus blood and urine complement biomarkers. A prior Phase 1 study in healthy volunteers showed weekly 450 mg dosing achieved target tissue exposures without inhibiting complement in blood and was generally well-tolerated. Akebia acquired global rights to ebribafusp from Q32 Bio in November 2025 and expects initial Phase 2 data in 2027 (NCT06419205).
Akebia Therapeutics (Nasdaq: AKBA) will release its second quarter 2026 financial results for the period ended June 30, 2026, on Wednesday, August 5, 2026, after the market close.
The company will host a conference call the same day at 4:30 p.m. EDT, accessible by phone using passcode 4727037 or via live webcast and archived replay in the Investors section of its website.
Akebia Therapeutics (Nasdaq: AKBA) granted stock options to 3 new employees as inducement awards under Nasdaq Listing Rule 5635(c)(4). The options cover an aggregate 125,600 shares at a per-share exercise price of $1.14, equal to the June 30, 2026 closing price.
Options vest over four years: 25% on the first anniversary, then 75% quarterly, subject to continued service, with a 10-year term under Akebia’s inducement award program and option agreements.
Akebia Therapeutics (Nasdaq: AKBA) and U.S. Renal Care reported an interim analysis of the 2,116‑patient VOICE trial in U.S. dialysis patients with CKD anemia. Vafseo (vadadustat) dosed three times weekly showed improved safety outcomes versus ESAs, meeting prespecified stopping criteria.
The primary composite endpoint of all‑cause mortality and hospitalization showed win odds of 1.16 (95% CI 1.06–1.28; p=0.0016), establishing non‑inferiority and superiority. Hospitalizations decreased to 1.11 vs 1.23 per patient‑year (IRR 0.90), with no significant mortality difference. Vafseo was FDA‑approved in March 2024 and is the only oral HIF‑PHI for anemia in the U.S.
Akebia Therapeutics (Nasdaq: AKBA) announced a new Orange Book–listed patent for Vafseo (vadadustat) and eligibility for a 5-year extension of a composition of matter patent. Akebia now has 14 Vafseo patents listed with expirations out to 2036, supporting its anemia-in-dialysis franchise.
Akebia Therapeutics (Nasdaq: AKBA) granted a stock option inducement award to one newly hired employee under Nasdaq Listing Rule 5635(c)(4). The option covers 8,400 shares at an exercise price of $1.02 per share, vests over four years, and has a 10-year term.
Akebia Therapeutics (Nasdaq: AKBA) announced that Chief Financial and Business Officer Erik Ostrowski and Chief Commercial Officer Nicholas Grund will present at the 2026 Jefferies Global Healthcare Conference on June 4, 2026, at 7:35 AM ET in New York.
A live and 90-day replay webcast will be available via Akebia's investor website.
Akebia (Nasdaq: AKBA) reported Q1 2026 results: Vafseo net product revenues $15.8M, total net product revenues $52.0M, and total revenues $53.5M. Patients on Vafseo rose ~60% vs Q4 2025 and prescribers reached ~1,025 (+28%). Company reiterated pipeline progress with praliciguat Phase 2 enrollment and planned AKB-097 and AKB-9090 studies.
Q1 net loss was $9.1M, COGS rose to $12.3M driven by inventory write-downs, and cash was ~$162.6M with a stated runway of at least two years.